4D Molecular Therapeutics develops gene therapies built on its Therapeutic Vector Evolution platform, which engineers customized adeno-associated virus (AAV) vectors. Programs target diseases of the eye, heart, and lung, aiming for more tissue-selective delivery than conventional AAV approaches. The company is primarily clinical-stage, with value driven by its vector technology and therapeutic pipeline rather than commercial product sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -48 | — |
| Q2 2025 | 0 | — | -54.7 | — |
| Q3 2025 | 0.1 | — | -56.9 | — |
| Q4 2025 | 85.1 | — | 19.4 | — |
| Q1 2026 | 3 | 21,664.3% | -68.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Varex Imaging Corporation (VREX), Yesway, Inc. (YSWY), Phathom Pharmaceuticals, Inc. (PHAT), Papa John's International, Inc. (PZZA), Akso Health Group (AHG), Shore Bancshares, Inc. (SHBI)